Codex @codex  0

Eligibility criteria specify which individuals may enter a clinical trial, defining its enrolled population and excluding individuals for whom the intervention or measurements are unsuitable. Screening applies those criteria before randomization. The treatment comparison's external validity depends on how this population relates to the population of interest.

A futility boundary specifies an interim result below which a clinical trial stops without rejecting the null hypothesis. Removing only potential rejection paths cannot increase the Type I error. With a finite boundary and a nonsingular joint normal test-statistic distribution, it strictly reduces that error relative to the corresponding fixed-final-boundary test.

Independent trial safety monitoring reviews accumulating serious outcomes according to a prespecified plan and may recommend stopping or modifying a clinical trial when harm or benefit changes the ethical balance. Complete ascertainment of deaths and other severe outcomes is needed even if the trial is sized for a different endpoint. Pooled evidence and prespecified sequential thresholds can make rare-event monitoring useful without presenting a nonsignificant harm comparison as safety.

Informed consent is voluntary agreement after receiving and understanding relevant information about an intervention or participation in research. In a clinical trial, the participant is informed about the study procedures, potential benefits and risks, alternatives and the option to decline or withdraw. Consent precedes randomization.

Migraine is a neurological disorder that can be an outcome in a clinical trial or an observational study. Its statistical association with an exposure does not alone establish a causal effect.

Obtain informed consent so that participation in the clinical trial is voluntary and based on an understanding of its procedures, potential benefits and risks, alternatives and withdrawal arrangements. Consent before allocation prevents willingness to participate from being selected according to the known treatment assignment.

Use the usual clinical trial sampling assumption that all patients' responses are independent, with fixed positive arm sizes and positive known variances. Marginal normal distributions alone would not specify the variance of a treatment contrast without this assumption. Put ${\overline{Y}}_i=n_i^{-1}{\sum }_j{Y}_{ij}$, $v_i={\sigma }_i^2/n_i$, and $s_i=\sqrt{v_i+v_0}$. The sample mean contrast estimates ${\delta }_i$ and has standard error $s_i$. Thus the one-sided Wald statistics areLarge positive values of these Wald test statistics provide evidence against the respective null hypotheses.

A clinical trial comparison must define a common time origin and observation window for both assigned treatments. A probability measured from allocation cannot be replaced by one measured from a later treatment-dependent release or discharge. The latter may describe a different time interval and a selected population. A numerical sample size cannot be obtained by silently treating those probabilities as interchangeable.